On February 4, 2020, BenchSci completed its US$22 million Series B financing round led by F-Prime Capital. The funding will be used to launch new offerings including an AI-assisted reagent selection product, and an expansion of its contract with Novartis.
BenchSci is a technology firm specialized in healthcare technology focused on using biomedical artificial intelligence to help researchers run successful experiments.
F-Prime Capital is an investment firm specialized in investments in healthcare and technology focused growth stage companies.
Osler, Hoskin & Harcourt LLP advised BenchSci with a team consisting of Chad Bayne, Justin Dharamdial and Shalu Atwal (Emerging and High Growth Companies).
Key Contact
Partner, Emerging and High Growth Companies, Toronto
Team
Partner, Emerging and High Growth Companies, Toronto
